Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07720375 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

Name: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis — clinical trial record (NCT07720375)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATMOS

StatusRecruiting

PhasePhase 2

SponsorUCB Biopharma SRL

Started2026-08-05

View on ClinicalTrials.gov ↗

Amendment history

2026-09-10

Study Status, Eligibility, Contacts/Locations v3

Study sites3→4

Eligibility criteria+1 characters

[...] udy participant has an absolute neutrophil count (ANC) <1.5×~~103~~10^3/μL. This test can be repeated once

2026-08-06

Study Status, Eligibility, Contacts/Locations v2

Recruitment opened

Trial sites expanded: 0 → 3 locations

Start dateestimated 2026-07-31→confirmed 2026-08-05

2026-07-22

Study Identification, Study Status v1

Re-verified, no change to tracked fields

2026-07-17

Original filing

UCB Biopharma SRL

68 trials monitored

See 4 trials at risk

The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)

Trial Details

NCT Number	NCT07720375
Lead Sponsor	UCB Biopharma SRL
Conditions	Non-cystic Fibrosis Bronchiectasis
Enrollment	300 participants
Start Date	2026-08-05
Primary Completion	2029-02-28 (estimated)
Study Completion	2029-04-26 (estimated)
Updated on ClinicalTrials.gov	2026-09-11